Prenatal cannabis exposure - The “first hit” to the endocannabinoid system Kimberlei A. Richardson, Allison K. Hester, Gabrielle L. McLemore Neurotoxicology and Teratology, 2016, 58, 5-14. DOI : 10.1016/j.ntt.2016.08.003 © 2016 Elsevier Inc. All rights reserved Abstract : As more states and countries legalize medical and/or adult recreational marijuana use, the incidences of prenatal cannabis exposure (PCE) will likely increase. While young people increasingly view marijuana as innocuous, marijuana preparations have been growing in potency in recent years, potentially creating global clinical, public health, andworkforce concerns. Unlike fetal alcohol spectrumdisorder, there is no phenotypic syndrome associated with PCE. There is also no preponderance of evidence that [...]
Lire la suiteUsing CBD to Tame a Cannabis High? Small Doses May Have the Opposite Effect Bailey Rahn, February 28, 2019, https://www.leafly.com Posted By Bailey Rahn On February 28, 2019 @ 3:52 pm In Science & Tech https://www.leafly.com/news/science-tech/how-cbd-dose-affects-cannabis-effects/print/ (imaginima/iStock) Take some CBD, they said. You’ll feel less high, they said. This common piece of advice fed to THC-shy consumers can effectively bring someone back down to earth. It works—sometimes. But new research shows there’s likely more nuance in the solution than we initially thought. Scientists found that a high dose of CBD dampened the effects of a THC high, but participants reported a stronger high when combined with low [...]
Lire la suiteNo significant effect of cannabis use on the count and percentage of circulating CD4 T-cells in HIV-HCV co-infected patients (ANRS CO13-HEPAVIH French cohort) Fabienne MARCELLIN, Caroline LIONS, Eric ROSENTHAL, Perrine ROUX, Philippe SOGNI, Linda WITTKOP, Camelia PROTOPOPESCU, Bruno SPIRE, Dominique SALMON-CERON, François DABIS, Maria Patrizia CARRIERI, & HEPAVIH ANRS CO13 STUDY GROUP (10Paris Descartes University, Paris, France) Drug and Alcohol Review (2016) DOI: 10.1111/dar.12398 Abstract : Introduction and Aims. Despite cannabis use being very common in patients co-infected with HIV and hepatitis C virus (HCV), its effect on these patients’ immune systems remains undocumented. Documenting the potential effect of cannabis use on HIV immunological markers [...]
Lire la suiteEffets, risques et dommages https://www.norml.fr/sante-prevention-rdr/effets-et-risques/ Fleur de cannabis en début de floraison. On peut apercevoir une multitude de petits points blancs sur les feuilles, ce sont les trichomes qui contiennent entre autre, le THC et le CBD. Menu de la page : Effets du cannabis Risques à court terme Risques à moyen terme Risques à long terme Synthèse des dommages https://www.norml.fr/sante-prevention-rdr/effets-et-risques/prevention-rdr/effets-et-risques/ Les effets du chanvre Les principes actifs du chanvre peuvent être bénéfiques pour la santé dans de nombreuses pathologies (voir chanvre et médecine) mais ce sont surtout les effets psychoactifs qui sont recherchés par les usagers non médicaux. L’usage de chanvre entraîne classiquement une sensation d’euphorie [...]
Lire la suiteLe cannabidiol (épisode 2) http://addictovigilance.aphp.fr/2019/04/09/le-cannabidiol-episode-2/ 09/04/2019 Après l’épisode 1 sur le cannabidiol, le CEIP-A de Paris propose l’épisode 2 Une mise à jour des données sur le CBD a permis de mettre en lumière de nouvelles informations que nous souhaitons communiquer à travers l’épisode 2 de notre série d’articles sur le cannabidiol (CBD). Depuis le début du mois de décembre 2018 l’Epidyolex®, un médicament sous forme de solution buvable contenant du CBD dosé à 100mg/mL, est disponible en France. Il dispose d’une Autorisation Temporaire d’Utilisation (ATU) dans l’indication du traitement des convulsions insuffisamment contrôlées par les traitements actuels dans le syndrome de Lennox-Gastaut et dans [...]
Lire la suiteLe cannabidiol (épisode 1) http://addictovigilance.aphp.fr/2018/11/09/le-cannabidiol-episode-1/ 09/11/2018 Depuis plusieurs mois, de nombreux « coffee-shops » ont ouvert un peu partout en France : 120 selon les estimations de l’association Norml. Ce sont des boutiques où il est possible d’acheter et consommer du cannabis. En France, étant donné que le cannabis est illégal, les coffee-shops proposent des produits à base de cannabidiol, substance présente dans le cannabis, mais non nommément désignée dans la liste des stupéfiants en France. L’ouverture de ces coffee-shops suscite le débat et face à l’ampleur du phénomène, les autorités sanitaires (MILDECA, ANSM, etc…) ont apporté une clarification sur la règlementation de ces produits [1]. Norml: National [...]
Lire la suiteThe Endocannabinoid System and Cannabidiol’s Promise for the Treatment of Substance Use Disorder Yann Chye, Erynn Christensen, Nadia Solowij, and Murat Yücel Frontiers in Psychiatry, 19 February 2019, doi: 10.3389/fpsyt.2019.00063 Substance use disorder is characterized by repeated use of a substance, leading to clinically significant distress, making it a serious public health concern. The endocannabinoid system plays an important role in common neurobiological processes underlying substance use disorder, in particular by mediating the rewarding and motivational effects of substances and substance-related cues. In turn, a number of cannabinoid drugs (e.g., rimonabant, nabiximols) have been suggested for potential pharmacological treatment for substance dependence. Recently, cannabidiol [...]
Lire la suiteA cannabis reader : global issues and local experiences. Perspectives on cannabis controversies, treatment and regulation in Europe EMCDDA MONOGRAPHS, 8 Volume 1 Editors : Sharon Rödner Sznitman, Börje Olsson, Robin Room European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 2008 — 392 pp. Contents Introduction Foreword : Wolfgang Götz Overview of Volume 1 : Sharon Rödner Sznitman and Börje Olsson Part I : Cannabis in the past Chapter 1 : Cannabis as medicine in Europe in the 19th century : Manfred Fankhauser Chapter 2 : The re-emergence of the therapeutic use of cannabis products : recent developments and future prospects : John Witton Chapter 3 : The pharmacology of cannabis: [...]
Lire la suiteThe Treatment of Cannabis Use Disorder Itai Danovitch, David A. Gorelick, Chapter,The Assessment and Treatment of Addiction, january 2019 Abstract: Worldwide, cannabis is the most commonly used illicit substance. Approximately 8-12% of persons who use cannabis will develop cannabis use disorder (CUD) at some point in their life. Several psychosocial treatment methods have shown efficacy in controlled clinical trials, including motivational enhancement therapy, cognitive behavioral therapy, and contingency management. While no pharmacotherapy has been established as broadly effective for CUD, gabapentin and N-acetylcysteine have shown efficacy in single controlled clinical trials, and a number of promising approaches are under study. This article reviews established [...]
Lire la suiteCannabis Use Disorder During the Perinatal Period Martha L. Velez, Chloe J. Jordan, and Lauren M. Jansson Chapter 17, in : I. D. Montoya, S. R. B. Weiss (eds.), Cannabis Use Disorders, 2019, © Springer Nature Switzerland AG 2019 177 https://doi.org/10.1007/978-3-319-90365-1_17 Introduction Cannabis use in the perinatal period has been increasing in recent years, coincident with increasing legalization in the USA for medical or recreational purposes [1]. Marijuana is the most commonly used illicit drug during pregnancy [2], and among some populations, it is used more frequently than tobacco [3, 4]. Although the prevalence of cannabis use during pregnancy is difficult to ascertain with accuracy, [...]
Lire la suite